BBT-207

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

5mo

BBOTPhase 2$825M

BBT-207 Phase 2 Results Expected

BBT-207• EGFR Mutant Advanced Non-Small Cell Lung Cancer24

Aug 1Estimated

00%

Competitive Landscape

0 competitors in EGFR Mutant Advanced Non-Small Cell Lung Cancer

Drug Information

Target Indication

EGFR Mutant Advanced Non-Small Cell Lung Cancer

Clinical Trial

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

BBOT

BridgeBio Oncology Therapeutics, Inc.

Related Pipeline

Amyloidosis

Amyloid Cardiomyopathy, Transthyretin-Related

Autosomal Dominant Hypocalcemia (ADH)

Achondroplasia

Idiopathic Pulmonary Fibrosis